Physician profile
Donald D Graham
NPI 1497737621
$3,636.64
in general payments reported to CMS, 2019-2025
24 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $130 · 2021: $446 · 2022: $352 · 2023: $885 · 2024: $982 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,434 · Education: $95.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,434.02 |
| Education | $95.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,073.37 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $989.45 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $320.14 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.50 | 2021-2024 | Ofev |
| Genzyme Corporation | $98.85 | 2023-2025 | |
| Csl Behring | $81.05 | 2020-2024 | Hizentra |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Insmed, INC. | $74.07 | 2024-2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $73.75 | 2020-2025 | Glassia, Hyqvia |
| Mallinckrodt Hospital Products INC. | $69.62 | 2023-2025 | Acthar |
| Mylan Specialty L.P. | $67.94 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $66.80 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $64.38 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Gilead Sciences, INC. | $62.00 | 2023-2024 | Veklury |
| Shire North American Group INC | $50.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $45.72 | 2024-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $41.49 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $35.96 | 2024 | Wegovy |
| Mallinckrodt Enterprises LLC | $27.44 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.01 | 2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $19.99 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $17.53 | 2019 | |
| Pulmonx Corporation | $16.21 | 2020 | |
| Advanced Respiratory, INC | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.